InterMune Inc: All Recent News

• All recent news
• Earnings news

Market Report -- Short Stories (ITMN) 11/19/2009

InterMune: Wedbush discusses ITMN-191's implications of ITMN, VRUS, and VRTX . Wedbush notes that yesterday a dose group in the Phase IIb study of ITMN-191+P/R was disontinued. They estimate that the... Briefing.com

UPDATE 2-InterMune to modify hep C study to drop one dosage 11/17/2009

... At Thomson Reuters

InterMune shares fall on change in hepatitis study 11/17/2009

NEW YORK (AP) - Shares of InterMune Inc. fell Tuesday after the biotechnology company said it would discontinue a high-dose of its experimental Hepatitis C treatment in a study because of potential liver damage. Associated Press

Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz 11/17/2009

Mipomersen lowers cholesterol but not without liver side effects. At TheStreet.com

InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz 11/17/2009

Safety monitors force change to mid-stage study of ITMN-191... At TheStreet.com

InterMune Announces Modification to On-Going Phase 2b Study of... 11/17/2009

BRISBANE, Calif., Nov. 17 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of... PR Newswire

InterMune Reports Third Quarter 2009 Financial Results and... 11/5/2009

BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2009.InterMune... PR Newswire

InterMune Announces Appointments of Senior Leadership to... 11/5/2009

BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced additions to its senior leadership team to prepare for the potential commercialization of pirfenidone... PR Newswire

InterMune Announces Submission of NDA for Pirfenidone for the... 11/4/2009

BRISBANE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug... PR Newswire

INFORM-1 Results: Robust Antiviral Suppression Achieved with... 11/3/2009

- Significant antiviral potency in both naive and treatment-failure patients -- Promising safety and tolerability -- Phase 2 studies to begin in Q1 2010 -BOSTON, Nov. 3 /PRNewswire-FirstCall/ --... PR Newswire

INFORM-1 Results: Robust Antiviral Suppression Achieved with... 11/3/2009

- Significant antiviral potency in both naive and treatment-failure patients -- Promising Safety and Tolerability -- Phase 2 studies to begin in Q1 2010 -BOSTON, Nov. 3 /PRNewswire-FirstCall/ --... PR Newswire

Earnings? Yawn. Trial Data? Moving! 10/30/2009

For Human Genome Sciences investors, the anticipation is frightening. At Motley Fool

InterMune to Present at Oppenheimer Conference 10/29/2009

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the... PR Newswire

InterMune to Release Third Quarter Financial Results on November 5 10/29/2009

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2009 financial results on Thursday, November 5, 2009 at 4:00 p.m. PR Newswire

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status